RVPH 250117 4.50P (RVPH250117P4500) Stock Options, News & Quotes

US OptionsDetailed Quotes

RVPH250117P4500

Watchlist

2.81
0.000.00%

15min DelayTrading Jan 17 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

H.C. Wainwright Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Cuts Target Price to $7
Moomoo News06:34 ET · Ratings
Express News | D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target
BenzingaJan 21 07:29 ET
Maxim Group Initiates Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Announces Target Price $7
Moomoo NewsJan 11 07:32 ET · Ratings
Maxim Group Upgrades Reviva Pharmaceuticals(RVPH.US) to Buy Rating, Announces Target Price $7
Moomoo NewsJan 10 08:33 ET · Ratings
Reviva Pharmaceuticals Upgraded to Buy From Hold at Maxim
TipRanksJan 10 08:21 ET · Ratings
Express News | Reviva Pharmaceuticals Holdings Inc : Maxim Group Raises to Buy From Hold
ReutersJan 10 07:28 ET

Comments

Clintzilla

Jan 16 09:05

$Reviva Pharmaceuticals (RVPH.US)$ Institutions steal the whole float yet?

iDontKnowHowToTrade

Jan 2 09:23

$Reviva Pharmaceuticals (RVPH.US)$ LET IT FLYYY

Trytosaveabit

Dec 16, 2024 16:25

Of course! Hehehe

$Reviva Pharmaceuticals (RVPH.US)$ Reviva Announces Proposed Public Offering
GlobeNewswire· 6 mins ago

Jaguar8

Dec 16, 2024 07:00

NEWS

$Reviva Pharmaceuticals (RVPH.US)$
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
Monday, 16th December at 8:00 am
– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year –
– Generally well-tolerated with low rates of adverse events and discontinuation –
– Full data set from open-label extension (OLE) of R...

Jaguar8

Dec 15, 2024 20:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...